Pfizer Inc. (NYSE:PFE) Shares Sold by Intech Investment Management LLC

Intech Investment Management LLC lowered its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 16.3% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 607,722 shares of the biopharmaceutical company's stock after selling 117,941 shares during the quarter. Intech Investment Management LLC's holdings in Pfizer were worth $17,587,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Olistico Wealth LLC acquired a new position in Pfizer in the second quarter worth $25,000. MFA Wealth Advisors LLC acquired a new position in shares of Pfizer in the 2nd quarter valued at about $29,000. Gladius Capital Management LP grew its position in shares of Pfizer by 102.8% during the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company's stock valued at $30,000 after buying an additional 38,015 shares during the last quarter. Quarry LP acquired a new stake in Pfizer during the second quarter worth about $31,000. Finally, Financial Connections Group Inc. acquired a new position in Pfizer in the second quarter valued at approximately $34,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on PFE shares. Citigroup began coverage on Pfizer in a research report on Friday, October 25th. They set a "neutral" rating and a $30.00 price target on the stock. Daiwa America raised shares of Pfizer from a "moderate buy" rating to a "strong-buy" rating in a report on Wednesday, August 7th. Sanford C. Bernstein assumed coverage on shares of Pfizer in a report on Thursday, October 17th. They issued a "market perform" rating and a $32.00 price objective on the stock. Daiwa Capital Markets upgraded shares of Pfizer from a "neutral" rating to an "outperform" rating and upped their target price for the stock from $28.00 to $34.00 in a research report on Wednesday, August 7th. Finally, Barclays boosted their price objective on Pfizer from $30.00 to $32.00 and gave the stock an "equal weight" rating in a research report on Wednesday, July 31st. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Pfizer currently has a consensus rating of "Moderate Buy" and a consensus target price of $32.92.

Pfizer Stock Performance

NYSE:PFE opened at $24.95 on Thursday. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The company has a 50-day moving average of $28.36 and a 200-day moving average of $28.61. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The firm has a market cap of $141.36 billion, a price-to-earnings ratio of 33.71, a price-to-earnings-growth ratio of 0.80 and a beta of 0.67.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The firm had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. During the same quarter in the previous year, the business posted ($0.17) earnings per share. The firm's quarterly revenue was up 31.2% compared to the same quarter last year. Analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be given a $0.42 dividend. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.73%. Pfizer's dividend payout ratio (DPR) is 227.03%.

Insider Buying and Selling

In other news, Director Scott Gottlieb acquired 1,000 shares of the firm's stock in a transaction that occurred on Wednesday, October 30th. The stock was purchased at an average price of $28.24 per share, with a total value of $28,240.00. Following the purchase, the director now owns 10,000 shares of the company's stock, valued at approximately $282,400. This trade represents a 11.11 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.06% of the stock is currently owned by company insiders.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.